-
公开(公告)号：US08183238B2
公开(公告)日：2012-05-22
申请号：US12816612
申请日：2010-06-16
申请人： Michelle M. Claffey , Amy B. Dounay , Matthew M. Hayward , Suobao Rong , Patrick R. Verhoest , Jamison B. Tuttle , Xinmin Gan
发明人： Michelle M. Claffey , Amy B. Dounay , Matthew M. Hayward , Suobao Rong , Patrick R. Verhoest , Jamison B. Tuttle , Xinmin Gan
IPC分类号： A61K31/52 , A61K31/519 , A61K31/5377 , A61K31/4375 , A61K31/473 , A61K31/4741 , A61K31/506 , A61K31/501 , A61K31/517 , C07D473/30 , C07D473/20 , C07D413/12 , C07D405/10 , C07D401/10 , C07D401/04 , C07D471/04 , C07D215/58 , C07D221/10 , C07D413/10 , C07D491/048 , C07D487/04
CPC分类号： C07D215/60 , C07D401/04 , C07D401/12 , C07D405/04 , C07D471/04 , C07D491/04
摘要： Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
摘要翻译： 式X的化合物：其中A，X，Y，Z，R 5，R 6a和R 6b如本文所定义，及其药学上可接受的盐被描述为可用于治疗与精神分裂症和其它神经变性和/或其它神经变性相关的认知缺陷 包括人在内的哺乳动物的神经障碍。
-
公开(公告)号：US20100324043A1
公开(公告)日：2010-12-23
申请号：US12816612
申请日：2010-06-16
申请人： Michelle M. Claffey , Amy B. Dounay , Matthew M. Hayward , Suobao Rong , Patrick R. Verhoest , Jamison B. Tuttle , Xinmin Gan
发明人： Michelle M. Claffey , Amy B. Dounay , Matthew M. Hayward , Suobao Rong , Patrick R. Verhoest , Jamison B. Tuttle , Xinmin Gan
IPC分类号： A61K31/5377 , C07D471/04 , A61K31/4375 , C07D215/58 , A61K31/4704 , C07D221/10 , A61K31/473 , C07D413/10 , C07D491/048 , A61K31/4741 , C07D401/12 , C07D401/10 , C07D405/10 , A61K31/506 , A61K31/501 , C07D413/12 , A61K31/517 , C07D487/04 , A61K31/519 , C07D473/30 , A61K31/52 , A61P25/00 , A61P25/18 , A61P25/16 , A61P9/10 , A61P25/30 , A61P25/28 , A61P25/24 , A61P27/02 , A61P29/00 , A61P35/00 , A61P13/00
CPC分类号： C07D215/60 , C07D401/04 , C07D401/12 , C07D405/04 , C07D471/04 , C07D491/04
摘要： Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
摘要翻译： 式X的化合物：其中A，X，Y，Z，R 5，R 6a和R 6b如本文所定义，及其药学上可接受的盐被描述为可用于治疗与精神分裂症和其它神经变性和/或其它神经变性相关的认知缺陷 包括人在内的哺乳动物的神经障碍。
-
公开(公告)号：US08598200B2
公开(公告)日：2013-12-03
申请号：US13307636
申请日：2011-11-30
IPC分类号： A01N43/42 , A61K31/44 , A01N43/40 , A61K31/445 , A01N43/56 , A61K31/415
CPC分类号： C07D471/04 , C07D487/04
摘要： Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
-
公开(公告)号：US20120302599A1
公开(公告)日：2012-11-29
申请号：US13307636
申请日：2011-11-30
IPC分类号： A61K31/437 , A61P25/00 , A61P9/10 , A61P9/04 , A61P25/28 , A61P21/02 , A61P25/08 , A61P25/06 , A61P13/02 , A61P25/30 , A61P25/16 , A61P27/02 , A61P25/18 , A61P25/24 , A61P25/22 , A61P31/00 , A61P37/00 , A61P1/16 , A61P35/00 , A61P27/16 , A61P1/08 , A61P25/14 , C07D471/04
CPC分类号： C07D471/04 , C07D487/04
摘要： Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.
摘要翻译： 式I化合物：其中X，Y，Z，R 1，R 2，R 3，R 4如本文所定义，及其药学上可接受的盐被描述为可用于治疗与精神分裂症和其他精神病学，神经变性和/ 或哺乳动物包括人类的神经障碍。
-
-
-
搜索结果
4 条记录 (耗时 0.032 秒)
